Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: A meta-analysis

Pharmacogenomics

Volumn 15, Issue 1, 2014, Pages 49-60

  Jung, Jin A ^a   Lim, Hyeong Seok ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adjuvant; Breast cancer; CYP2D6; Hazard ratio; Recurrence risk; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CYP2D6 GENE; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; META ANALYSIS; POSTOPERATIVE PERIOD; RECURRENCE RISK; TREATMENT OUTCOME;

BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84890519662     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.221     Document Type: Article

References (69)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
2. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White IN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23(11), 1897-1901 (2002). (Pubitemid 35355938)
3. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30(8), 869-874 (2002). (Pubitemid 34815415)
4. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system invitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062-1075 (2004). (Pubitemid 39108928)
5. Coller JK, Krebsfaenger N, Klein K et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 54(2), 157-167 (2002). (Pubitemid 35024939)
6. Fabian C, Tilzer L, Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm. Drug Dispos. 2(4), 381-390 (1981). (Pubitemid 12223758)
7. Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85(2), 151-159 (2004). (Pubitemid 38987269)
8. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758-1764 (2003). (Pubitemid 38008898)
9. Gjerde J, Gandini S, Guerrieri-Gonzaga A et al. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res. Treat. 134(2), 693-700 (2012).
10. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 23-37 (2004). (Pubitemid 38161221)
11. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002). (Pubitemid 34223859)
12. Sachse C, Brockmoller J, Hildebrand M, Muller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 8(2), 181-185 (1998). (Pubitemid 28227325)
13. Sakuyama K, Sasaki T, Ujiie S et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos. 36(12), 2460-2467 (2008).
14. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9(6), 669-682 (1999). (Pubitemid 30011931)
15. Del Re M, Michelucci A, Simi P, Danesi R. Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat. Rev. 38(5), 442-450 (2012).
16. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278(1), 441-446 (1996). (Pubitemid 27167124)
17. Mürdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89(5), 708-717 (2011).
18. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
19. Irvin WJ, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24), 3232-3239 (2011).
20. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25(25), 3837-3845 (2007). (Pubitemid 47477258)
21. Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28(8), 1287-1293 (2010).
22. Park IH, Ro J, Park S et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. 131(2), 455-461 (2012).
23. Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial. J. Natl Cancer Inst. 104(6), 441-451 (2012).
24. Rae JM, Drury S, Hayes DF et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst. 104(6), 452-460 (2012).
25. Thompson AM, Johnson A, Quinlan P et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125(1), 279-287 (2011).
26. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
27. Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115(5), 952-961 (2009).
28. Xu Y, Sun Y, Yao L et al. Association between CYP2D6 10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19(8), 1423-1429 (2008).
29. Sukasem C, Sirachainan E, Chamnanphon M et al. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac. J. Cancer Prev. 13(9), 4549-4553 (2012).
30. Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 14(18), 5913-5918 (2008).
31. Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D610 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J. Clin. Oncol. 39(10), 651-656 (2009).
32. Lash TL, Cronin-Fenton D, Ahern TP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J. Natl Cancer Inst. 103(6), 489-500 (2011).
33. Lash TL, Cronin-Fenton D, Ahern TP et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 49(3), 305-312 (2010).
34. Goetz MP, Schaid DJ, Wickerham DL et al. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin. Cancer Res. 17(21), 6944-6951 (2011).
35. Teh LK, Mohamed NI, Salleh MZ et al. Therisk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPSJ. 14(1), 52-59 (2012).
36. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284-R290 (2005).
37. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9(1), R7 (2007).
38. Bijl MJ, van Schaik RH, Lammers LA et al. The CYP2D64 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 118(1), 125-130 (2009).
39. Abraham JE, Maranian MJ, Driver KE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 12(4), R64 (2010).
40. Ramóny Cajal T, Altes A, Pare L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat. 119(1), 33-38 (2010).
41. Stingl JC, Parmar S, Huber-Wechselberger A et al. Impact of CYP2D64 genotype on progression free survival in tamoxifen breast cancer treatment. Curr. Med. Res. Opin. 26(11), 2535-2542 (2010).
42. Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother. Pharmacol. 70(1), 75-81 (2012).
43. Kiyotani K, Mushiroda T, Hosono N et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics 20(9), 565-568 (2010).
44. Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3), 249-258 (2005). (Pubitemid 40903087)
45. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312-9318 (2005).
46. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007). (Pubitemid 47555336)
47. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187-5193 (2007). (Pubitemid 350232249)
48. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D610 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99(5), 995-999 (2008). (Pubitemid 351997603)
49. Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res. Treat. 122(3), 609-617 (2010).
50. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat. Med. 18(3), 321-359 (1999).
51. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793), 771-784 (2011).
52. Hackshaw A, Roughton M, Forsyth S et al. Long-term benefits of 5years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50years of age with early breast cancer. J. Clin. Oncol. 29(13), 1657-1663 (2011).
53. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28(3), 509-518 (2010).
54. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12), 1135-1141 (2010).
55. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
56. Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2756 (2005).
57. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol. 18(Suppl. 8), 26-35 (2007).
58. Leung KM, Elashoff RM, Afifi AA. Censoring issues in survival analysis. Annu. Rev. Public Health 18, 83-104 (1997). (Pubitemid 27194065)
59. Efron B, Tibshirani R. An Introduction to the Bootstrap. Chapman & Hall/CRC, London, UK (1993).
60. Gonzalez-Santiago S, Zarate R, De La Haba-Rodriguez J, Gomez A, Bandres E, Borrega P. Genetic polymorphism CYP2D6(4) interaction in clinical outcomes of tamoxifen-treated breast cancer patients. Ann. Oncol. 17, 62-63 (2006).
61. Zeng Z, Liu Y, Liu Z et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer Chemother. Pharmacol. 72(2), 287-303 (2013).
62. Bratherton DG, Brown CH, Buchanan R et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10mg bd versus 20mg bd. Br. J. Cancer 50(2), 199-205 (1984). (Pubitemid 14061945)
63. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007). (Pubitemid 350116943)
64. Brauch H, Schroth W, Goetz MP et al. Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J. Clin. Oncol. 31(2), 176-180 (2013).
65. Loo LW, Ton C, Wang YW et al. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 47(12), 1049-1066 (2008).
66. Castells A, Gusella JF, Ramesh V, Rustgi AK. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res. 60(11), 2836-2839 (2000). (Pubitemid 30395802)
67. Hirano A, Utada Y, Haga S et al. Allelic losses as prognostic markers for breast cancers. Int. J. Clin. Oncol. 6(1), 6-12 (2001). (Pubitemid 32230356)
68. Ahmad A, Ali SM, Ahmad MU, Sheikh S, Ahmad I. Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res. Treat. 122(2), 579-584 (2010).
69. CYP2D6 allele nomenclature (2013).www.cypalleles.ki.se/cyp2d6. htm(Accessed 16 September 2013)